Accurate mediastinal staging remains a key component in the workup of patients with lung cancer, since treatment options and prognosis vary depending on the stage. While imaging studies continue to evolve, invasive mediastinal staging plays an important role in confirming nodal disease and ruling out false positives such as granulomatous lymph nodes. Thoracic surgeons must understand the advantages and disadvantages of each approach to mediastinal staging, the sensitivity and negative predictive value of different techniques, and the role of invasive mediastinal staging in the clinical decision making for different stages of lung cancer. While (EBUS-TBNA) has assumed a more prominent role over mediastinoscopy, it is important for surgeons to be facile with these techniques, the correct indications for their use, and when to proceed with mediastinoscopy despite a negative EBUS-TBNA if there continues to be high suspicion for mediastinal nodal disease. It is important that patients undergo appropriate mediastinal staging when indicated even when the planned treatment approach is stereotactic radiation or wedge resection because of poor pulmonary function or comorbidities, since the identification of stage III disease could alter the treatment approach.
INVASIVE MEDIASTINAL STAGING FOR NON-SMALL CELL LUNG CANCER
The indications to perform invasive mediastinal staging before a planned resection of a primary lung cancer depend on several factors. The first of these factors is the estimated prevalence of N2 metastases in the population, defined by clinical stage. The decision to perform invasive mediastinal staging is also affected by the performance of the imaging modality used for clinical staging, because both computed tomography (CT) and positron emission tomography (PET) are associated with significant false-positive and falsenegative rates. There will be more false-negative mediastinal lymph nodes when clinical staging is performed with CT as opposed to PET. 1 The sensitivity and specificity of EBUS-TBNA and mediastinoscopy for mediastinal lymph node metastases must also be considered. Because the sensitivity of a test is related to the prevalence of disease in the population, invasive mediastinal staging will be of greatest value in patients with a higher likelihood of N2 metastases. Another consideration is the presumed benefit of induction therapy versus postoperative adjuvant therapy for occult N2 disease.
In the absence of distant metastatic disease, staging of the mediastinal lymph nodes guides lung cancer treatment and determines prognosis. Despite the publication of lung cancer staging guidelines by the American College of Chest Physicians (ACCP), 2 the European Society of Thoracic Surgeons (ESTS), 3 and the National Comprehensive Cancer Network, 4 there continues to be significant variability and underuse of invasive mediastinal staging. 5 In a study of 15,316 patients in the Surveillance, Epidemiology, and End Results and Texas Cancer Registry Medicare-linked databases, only 21% of patients had guideline-consistent diagnostic evaluations, and 44% of patients never had mediastinal sampling. 6 Patients with guideline-consistent care underwent fewer tests and had fewer complications.
The local expertise with EBUS-TBNA or mediastinoscopy is also a consideration. If the test is not performed reliably, it is also of little value. Whether a test is performed completely can be just as important as what staging tests are chosen. Detterbeck and colleagues 7 have proposed a classification system for the thoroughness of mediastinal staging (complete, systematic, selective sampling, or poor).
MEDIASTINOSCOPY
Mediastinoscopy is the historical standard in mediastinal staging, and it provides access to lymph node stations It is a minimally-invasive surgical procedure performed under general anesthesia. The risk of hoarseness from recurrent laryngeal nerve injury and bleeding are low when performed by an experienced surgeon. Wei and colleagues reported results from 1,970 mediastinoscopies and found a sensitivity of 90% with a negative predictive value (NPV) of 92%, morbidity of 1.3%, and significant bleeding in 0.25%. 8 Procedures were performed as an outpatient in 96.1%. Mediastinoscopy may be useful and preferred in certain situations where mobilization of the proximal airway complements subsequent intrathoracic airway reconstruction. Surgeons should also be aware of situations where mediastinoscopy carries greater risk such as redo procedures and mediastinal fibrosis from radiation treatment.
Extended mediastinoscopy continues the dissection between the anterior aspect of the left innominate vein and the sternum over the aortic arch at the origin of the innominate artery, allowing additional access to stations 5 and 6. A Chamberlain procedure (anterior mediastinotomy), CT-guided biopsy, or a left thoracoscopic approach are also alternatives to biopsy stations 5 and 6. Transcervical extended mediastinal lymphadenectomy (TEMLA) and video-assisted mediastinal lymphadenectomy (VAMLA) allow a more extensive bimanual lymph node dissection with a sensitivity of 0.96 and NPV of 0.99 but have an increased risk of recurrent laryngeal nerve injury.
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ENDOBRONCHIAL ULTRASOUND WITH FINE NEEDLE ASPIRATION
EBUS-TBNA ( Figure 1 ) is an endoscopic procedure that can be performed with sedation and topical anesthesia and allows biopsies of stations 11R, 11L, 12R, and 12L in addition to the 2R, 2L, 4R, 4L, 7, 10R, and 10L lymph nodes accessible by mediastinoscopy ( Table 1) . Biopsies of small 11 An average of three lymph node stations were sampled per patient by EBUS-TBNA while four stations were sampled on average by mediastinoscopy. Agreement between EBUS-TBNA and mediastinoscopy results were excellent at 91% with a Kappa of 0.8 (95% CI 0.7-0.9). The sensitivity, NPV, and accuracy for mediastinoscopy were 79%, 90%, and 93% compared to EBUS-TBNA at 81%, 91%, and 93%. In centers with expertise, EBUS-TBNA can achieve similar results to mediastinoscopy. While the sensitivity of 79% and 81% was relatively low, this can likely be explained by the higher percentage of clinical stage I lung cancers (59%) in the study cohort with a lower prevalence of N2 disease resulting in a lower sensitivity. Studies have also shown increased accuracy with a higher number of aspirations per lymph node, and at least three passes or rapid-on-site evaluation by cytology are recommended. 12 A randomized trial of 241 patients comparing mediastinoscopy in 118 patients to EBUS-TBNA and endoscopic ultrasound-fine needle aspiration (EUS-FNA) followed by mediastinoscopy, if negative, in 123 patients has been reported in a European trial by Annema and colleagues. 13 Inclusion criteria included patients with potentially resectable lung cancer with either clinically positive mediastinal or hilar lymph nodes or central tumors. The sensitivity of 94% (95% CI 0.85-0.98) in the EBUS-TBNA/EUS-FNA group was significantly higher than mediastinoscopy with a sensitivity of 79% (95% CI 0.66-0.88). The NPV was 93% and 86%, respectively. A subgroup analysis of patients with clinically positive N2/N3 disease on PET-CT showed a sensitivity of 86% for EBUS-TBNA/EUS-FNA which increased to 97% when mediastinoscopy was added if EBUS-TBNA/EUS-FNA was negative. 14 Another randomized trial by Um and colleagues comparing EBUS-TBNA to mediastinoscopy reported a sensitivity of 88% (95% CI 0.78-0.94) for EBUS-TBNA and 81% (95% CI 0.78-0.94) for mediastinoscopy. 15 These results demonstrate that endosonographic biopsies followed by mediastinoscopy, if negative, may be the preferred strategy for mediastinal staging when N2 disease is suspected.
EBUS-TBNA should be followed by mediastinoscopy when cytology is non-diagnostic with the absence of lymphocytes or there is a high suspicion of N2 disease on CT or PET. When the suspicious lymph nodes are inaccessible by EBUS-TBNA, a Chamberlain procedure (anterior mediastinotomy) or a left thoracoscopic approach should be performed to sample stations 5 and 6 while station 7, 8, and 9 lymph nodes can be biopsied by EUS-FNA. A meta-analysis by Korevaar and colleagues evaluated the combination of EBUS-TBNA and EUS-FNA for mediastinal staging and found a sensitivity of 83% and an NPV of 91% with the addition of EUS-FNA leading to a mean increase in sensitivity of 12%. 16 Future advances in endoscopic techniques including impedance ultrasonography may further improve the sensitivity and specificity of mediastinal staging. Ultrasonographic criteria including the short axis, characteristics of the central hilum, heterogeneity, shape, contour, and evidence of necrosis may also be useful in predicting the likelihood of malignancy.
CLINICAL STAGE IIIA (T1-2N2; T3N1; T4N0-1)
The most straightforward scenario is defined by that of clinical stage IIIA disease. This is defined by either mediastinal lymph node enlargement (>1 cm on short axis) with or without increased uptake of F-fluoro-2-deoxy-d-glucose (FDG) on PET scan or increased FDG uptake in mediastinal lymph nodes which are not enlarged on CT (Figure 2 ). Invasive mediastinal staging is indicated in these scenarios as the pre-test probability of N2 metastases is high. However, presumed nodal metastases must be confirmed histologically. This is necessary because PET and CT have high false positive rates and relatively low sensitivity and specificity. In this scenario, EBUS-TBNA is preferred over mediastinoscopy as the first test to invasively stage the mediastinum. If the EBUS-TBNA is negative, a mediastinoscopy should be performed if suspicion for positive N2 disease remains high. This is a less invasive approach and reserves mediastinoscopy for potential restaging of the mediastinum following administration of induction therapy. The sensitivity of EBUS-TBNA has been shown to be lower at 67% after induction therapy. 17 CLINICAL STAGE II (T1abc-T2abN1; T2bN0, T3N0)
The next scenario to consider is that of patients with central lung cancers or with clinically positive N1 lymph nodes. It is often difficult to discern between central tumors and enlarged N1 lymph nodes. These patients most often are classified as clinical stage II. The false negative rate for PET and CT approaches 25% for mediastinal lymph node disease in this setting. [18] [19] [20] Given the high prevalence of N2 disease in this group of patients, invasive staging of the mediastinum with EBUS-TBNA or mediastinoscopy is indicated. EBUS-TBNA (with or without EUS-FNA) is recommended as the first choice if the expertise is available given its similar performance and decreased invasiveness.
CLINICAL STAGE IA (PERIPHERAL T1abcN0)
For clinical stage IA lung cancer, the false negative rate of a CT scan for N2 disease is approximately 10%. 21 The performance of PET/CT is better with a false negative rate in the range of 3-6%. [18] [19] [20] 22 Wang and colleagues have published a meta-analysis examining the NPV of PET/CT for occult N2 disease in clinical stage I lung cancer. 23 This meta-analysis included 10 studies with a cumulative total of 1122 patients. The negative predictive value of PET/CT for mediastinal lymph node metastases in clinical IA and IB lung cancer was 94% and 89%, respectively. Cerfolio and colleagues have previously examined the performance of mediastinoscopy and EBUS-TBNA for N2 disease in clinical stage IA lung cancer. 22 The prevalence of N2 disease in the stage IA lung cancer population in this study was approximately 5%, and the sensitivity of mediastinoscopy was 60%, which was quite good given that the sensitivity of a test is related to the prevalence of disease in a population. With the observed prevalence and sensitivity, the number needed to treat to detect one positive N2 lymph node was 33 patients. Therefore, invasive mediastinal staging can likely be omitted for patients with clinical stage IA lung cancer based on PET/CT staging. The prevalence of N2 disease is expected to be low in this setting while the sensitivity of mediastinoscopy and/or EBUS-TBNA is only moderate. The expected number to treat to detect one N2 nodal metastases would be expected to be approximately 25 to 40 patients dependent on the estimates of prevalence of N2 disease and sensitivity of mediastinoscopy or EBUS-TBNA that are used. In a prior decision analysis which investigated the utility of mediastinoscopy for clinical stage IA lung cancer in patients staged with PET scans, Meyers and colleagues determined that if prevalence of N2 disease is >10%, mediastinoscopy may lengthen life at a cost of <$100,000 per life year. 24 However, below this prevalence threshold, mediastinoscopy was not cost effective. In clinical stage IA lung cancer, the prevalence of N2 disease does not reach this threshold. While preoperative mediastinal staging is not recommended, systematic nodal sampling at the time of lung resection is still essential for appropriate pathologic staging, even in patients who are cN0.
CLINICAL STAGE IB (T2AN0)
More uncertain is whether invasive mediastinal staging is indicated for clinical stage IB lung cancer. Risk factors for occult N2 metastases include larger tumor size, central location, adenocarcinoma, lymphovascular invasion, and a higher standardized uptake value (SUV) on PET. 25 The performance of PET/CT may be worse in these scenarios with more false negative results. As previously demonstrated in the meta-analysis by Wang and colleagues occult N2 disease is found in up to 11% of patients with cT2N0 lung cancer after PET/CT staging. 23 With a higher prevalence of N2 disease, invasive mediastinal staging is of greater utility. Contemporary clinical practice guidelines recommend invasive mediastinal staging in these patients. 2, 3 One of us (FF) has previously conducted a study to examine the utility of mediastinoscopy in clinical stage I lung cancers at increased risk for mediastinal lymph node metastases. 26 The objective was to determine the prevalence of occult N2 metastases in patients with clinical T2N0 or clinical T1N0 lung cancer with an SUV >10 by PET/CT in order to determine if routine mediastinoscopy was justified in this group of patients. Ninety patients with lung cancer were prospectively studied with 81 patients clinical stage T2N0 and 9 patients T1N0 with an SUV >10. Of the 275 lymph node stations sampled with mediastinoscopy in these 90 patients, there was one positive N2 node. Therefore, the rate of positive mediastinoscopy was 1.1%. Lung cancer resection was performed in 86 of these patients while 4 had N2 disease detected at the time of surgery. Therefore, the total rate of N2 upstaging was 5.6%. Only 4.4% of positive lymph nodes were accessible by mediastinoscopy as there was one positive station 5 lymph node. The NPV of mediastinoscopy after PET/CT was 95%, only a 1% improvement over PET/CT alone, and the sensitivity of mediastinoscopy after a negative PET/CT was only 25% due to the low prevalence of disease. Therefore, the routine use of mediastinoscopy in patients with clinical N0 lung cancer may not be warranted, even if the tumor is clinical stage IB or intensely hypermetabolic. We advocate selective use of invasive mediastinal staging based on surgeon judgement.
CONCLUSIONS
Accurate mediastinal staging remains a critical component in the workup of patients with lung cancer since (Tables 2 and 3) . [2] [3] [4] If local expertise is available, the preferred strategy is to begin with EBUS-TBNA-guided biopsies followed by mediastinoscopy if non-diagnostic or there continues to be high suspicion for mediastinal nodal disease. Invasive staging is most clearly indicated in patients with mediastinal lymph nodes that are>1 cm or hypermetabolic on PET. In patients with central tumors or clinical N1 lymph node involvement on PET or CT, invasive staging is also indicated. For peripheral tumors greater than 3 cm in size that are clinical N0, the data is not conclusive. Invasive staging may benefit some but not all of these clinically diverse patients. More studies are needed in this subgroup of patients, and we recommend selective application of invasive staging at present. Finally, the data do not support the routine use of invasive mediastinal staging for clinical stage IA lung cancers.
